Association of norepinephrine transporter gene with methylphenidate response

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 43, Issue 9, 2004, Pages 1154-1158

  Yang, Li ^a   Wang, Yu Feng ^a   Li, Jun ^a   Faraone, Stephen V ^b,c  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Attention deficit hyperactivity disorder; Methylphenidate; Norepinephrine transporter gene

Indexed keywords

METHYLPHENIDATE; NORADRENALIN TRANSPORTER; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ADULT; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; ETHNIC GROUP; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERACTIVITY; MALE; NORADRENALIN RELEASE; NOREPINEPHRINE TRANSPORTER GENE; PRIORITY JOURNAL; RATING SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 4143072407     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000131134.63368.46     Document Type: Article

References (37)

1. American Academy of Child and Adolescent Psychiatry (1997), Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36(suppl):85S-121S
2. Barkley R (1998), Attention-Deficit Hyperactivity Disorder: A Clinical Workbook, 2nd ed. New York: Guilford
3. Barr CL, Kroft J, Feng Y et al. (2002), The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am J Med Genet 114:255-259
4. Bruss M, Kunz J, Lingen B, Bonisch H (1993), Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet 91:278-280
5. Bymaster FP, Katner JS, Nelson DL et al. (2002), Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
6. Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ (2002), Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther 301:1097-1102
7. Faraone SV, Doyle AE (2001), The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 10:299-316
8. Faraone SV, Sergeant J, Gillberg C et al. (2003), The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104-113
9. Faraone SV, Aleardi M (2004), Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24-29
10. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999), Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-402
11. Hanna GL, Ornitz EM, Hariharan M (1996), Urinary catecholamine excretion and behavioral differences in ADHD and normal boys. J Child Adolesc Psychopharmacol 6:63-73
12. Holm S (1979), A simple sequentially rejective multiple test procedure. Scand J Statistics 6:65-70
13. Hu YZ (1998), Subtyping and inquiring for etiology of children ADHD aged 6 to 12 years. Chin J School Doctor 12:321-324
14. Ishimatsu M, Kidani Y, Tsuda A, Akasu T (2002), Effects of methylphenidate on the membrane potential and current in neurons of the rat locus coeruleus. J Neurophysiol 87:1206-1212
15. Jones MD, Williams ME, Hess EJ (2001), Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant. Pharmacol Biochem Behav 68:669-676
16. Kleyn PW, Vessell ES (1998), Genetic variation as a guide to drug development. Science 281:1820-1821
17. Kuczenski R, Segal DS (1994), Neurochemistry of amphetamine. In: Amphetamine and Its Analogues: Psychopharmacology, Toxicology and Abuse, Cho AK, Segal DS, eds. San Diego: Academic Press, pp 81-113
18. Kuczenski R, Segal DS (2002), Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22:7264-7271
19. Li X (1993), Epidemiological study of mental health problems of 4-16 years old children in Hunan Province. Bull Hunan Med University 1:43-46
20. McEvoy B, Hawi Z, Fitzgerald M, Gill M (2002), No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. Am J Med Genet 114:665-666
21. Michelson D, Adler L, Spencer T et al. (2003), Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
22. Michelson D, Faries D, Wernicke J et al. (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83
23. Pacholczyk T, Blakely RD, Amara SG (1991), Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354
24. Porzgen P, Bonisch H, Bruss M (1995), Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun 215:1145-1150
25. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH (2002), Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12:497-499
26. Russell V, Allie S, Wiggins T (2000), Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Behav Brain Res 117:69-74
27. Shekim WO, Javaid J, Davis JM, Bylund DB (1983), Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine. Biol Psychiatry 18:707-714
28. Shekim WO, Bylund DB, Hodges K, Glaser R, Ray-Prenger C, Oetting G (1994), Platelet alpha 2-adrenergic receptor binding and the effects of d-amphetamine in boys with attention deficit hyperactivity disorder. Neuropsychobiology 29:120-124
29. Shen YC, Wang YF (1984), Urinary 3-methoxy-4-hydroxyphenylglycol sulfate excretion in seventy-three schoolchildren with minimal brain dysfunction syndrome. Biol Psychiatry 19:861-870
30. Shen YC, Wang YF, Yang XL (1985), An epidemiological investigation of minimal brain dysfunction in six elementary schools in Beijing. J Child Psychol Psychiatry 26:777-787
31. Spencer T, Biederman J, Wilens T et al. (1998), Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
32. Spencer T, Heiligenstein JH, Biederman J et al. (2002), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
33. Stober G, Nothen MM, Porzgen P et al. (1996), Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 67:523-532
34. Wall SC, Gu H, Rudnick G (1995), Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47:544-550
35. Wan GB (1993), Epidemiological study of attention deficit hyperactivity disorder of 7-16 years old children in Hunan province. Chin J Neurol Psychiatry 5:298-301
36. Winsberg BG, Comings DE (1999), Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477
37. Xin RE (1981), Study of minimal brain dysfunction in a sample of 700 children. Chin J Nerv Ment Dis 4:226-228